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Background: Although it is preferable that all patients with a recent Transient Ischemic Attack (TIA) undergo acute
carotid imaging, there are centers with limited access to such acute examinations. It is controversial whether
ABCD2 or ABCD3 scores can be used to triage patients to acute or delayed carotid imaging. It would be acceptable
that some patients with a symptomatic carotid stenosis are detected with a slight delay as long as those who will
suffer an early recurrent stroke are detected within 24 hours. The aim of this study is to analyze the ability of
ABCD2 and ABCD3 scores to predict ipsilateral ischemic stroke among patients with symptomatic 50-99% carotid
stenosis.
Methods: In this secondary analysis of the ANSYSCAP-study, we included 230 consecutive patients with
symptomatic 50-99% carotid stenosis. We analyzed the risk of recurrent ipsilateral ischemic stroke before carotid
endarterectomy based on each parameter of the ABCD2 and ABCD3 scores separately, and for total ABCD2 and
ABCD3 scores. We used Kaplan-Meier analysis.
Results: None of the parameters in the ABCD2 or ABCD3 scores could alone predict all 12 of the ipsilateral
ischemic strokes that occurred within 2 days of the presenting event, but clinical presentation tended to be a
statistically significant risk factor for recurrent ipsilateral ischemic stroke (p = 0.06, log rank test). An ABCD2 score ≥2
and an ABCD3 score ≥4 could predict all 12 of these strokes as well as all 25 ipsilateral ischemic strokes that
occurred within 14 days. To use ABCD3 score seems preferable over the ABCD2 score because a higher proportion
of low risk patients were identified (17% of the patients had an ABCD3 score <4 while only 6% had an ABCD2 < 2).
Conclusions: Although it is preferable that carotid imaging be performed within 24 hours, our data support that
an ABCD3 score ≥4 might be used for triaging patients to acute carotid imaging in clinical settings with limited
access to carotid imaging. However, our findings should be validated in a larger cohort study.
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Since its introduction in 2005 [1], the ABCD-score has
been thoroughly validated [2]. In large cohorts (n >
1 000), the score has been amended and validated with
parameters readily available in the emergency depart-
ment, namely diabetes [3,4] and dual events [4,5], and
with those requiring investigations, namely cerebral infarc-
tion on Computed Tomography or Magnetic Resonance
Imaging [4-6] and the presence of an ipsilateral ≥50%* Correspondence: elias.johansson@umu.se
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article, unless otherwise stated.carotid stenosis [4,5]. It has also been proposed to amend
the score based on large-artery atherosclerosis instead of
an ipsilateral ≥50% carotid stenosis [4]. In smaller co-
horts (n < 300), the addition of C-reactive protein [7], D-
dimer [8], hypertension [9], and hyperglycemia [9] have
been proposed but not validated. The validated amend-
ments have increased the ability of the scores to discrim-
inate risk: The ABCD2 score with diabetes is superior to
the ABCD score [3], the ABCD3 score with dual events
is superior to the ABCD2 score [5], and the ABCD3I
score with infarction on Computed Tomography and
Magnetic Resonance Imaging and the presence of antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ABCD3 score [5].
The exact role of the ABCD-type score in the manage-
ment of patients is unclear. One controversial issue is
whether ABCD-type scores can be used to triage pa-
tients to acute or delayed carotid imaging [5,8,10-15]. In
clinical settings where carotid imaging is available
(directly or by transfer), it has been proposed that all
patients with Transient Ischemic Attack (TIA) should
undergo acute carotid imaging within 24 hours [5].
However, at least in our experience, many clinical set-
tings have limited access to immediate carotid imaging
and acute transfer to centers with acute carotid imaging
is not feasible because of long distances and high costs.
In such clinical settings, there is a need for triaging pa-
tients to acute or delayed carotid imaging.
Several studies have shown that 31-48% of patients
with TIA or minor stroke with carotid stenosis have an
ABCD2-score <4 points, questioning the usefulness of
the ABCD2-score for triaging carotid imaging [14-17].
However, ABCD-type scores do not have to detect all
patients with symptomatic carotid stenosis as long as
they identify the patients with symptomatic carotid sten-
osis who will suffer a subsequent ipsilateral ischemic
stroke. Only one study has analyzed the ability of
ABCD2 to predict recurrent strokes (unspecified if is-
chemic or ipsilateral) among patients with symptomatic
carotid stenosis, but this study was limited by a small
sample size (n = 29 and 2 strokes) [18].
The aim of this study is to analyze the ability of the
ABCD2 and ABCD3 scores to predict recurrent ipsilat-




This is a secondary analysis of the Additional Neurological
SYmptoms before Surgery of the Carotid Arteries – a
Prospective study (ANSYSCAP) [19]. To date, the ANSYS-
CAP study was the largest single-center study of patients
with 50-99% carotid stenosis with up-to-date medical
prevention [19]. In short, the ANSYSCAP study pro-
spectively included 230 consecutive patients with symp-
tomatic 50-99% carotid stenosis. The patients were
included at the Umeå Stroke Center, Sweden, between
2007-08-01 and 2009-12-31. The sample size was derived
from setting study start- and stop dates. Most patients
(81%) were sent from 11 referring hospitals. We only in-
cluded patients that were preliminarily eligible for carotid
endarterectomy (CEA). This was defined as a patient
who underwent a pre-operative evaluation aimed at CEA.
Since this was a selected population, the CEA rate was
high (80%). Reasons for not performing CEA were low
predicted benefit (7%), too high perioperative risk due toco-morbidities or technical reasons (5%), CEA not mean-
ingful (4%) or patient refusal (4%). Over the course of the
study, CEA went from being most often scheduled to be
performed earlier. Whenever possible, the delay to CEA
was kept as short as possible. The observation period for
recurrent stroke was the first 90 days after the presenting
event in the primary analysis. For the majority of patients
that underwent CEA within 90 days, the observation time
was limited to up to the CEA. In order to reduce a pos-
sible bias caused by non-random censoring at CEA, the
current analysis was limited to the first 14 days after the
presenting event. The baseline characteristics of patients
are shown in Table 1. In the current analysis, we included
both patients with a presenting event lasting <24 hours
(TIA and amaurosis fugax) and ≥24 hours (stroke and
retinal artery occlusion) because our sample size was
small.
Data acquisition
In the original study, blood pressure was recorded at the
time of the pre-operative evaluation. The first blood
pressure should be used for the ABCD2 and ABCD3
scores. Therefore, we retrospectively amended our data
with the first recorded blood pressure. This was done by
a review of medical records. We recorded the patient’s
first documented blood pressure – most often at the first
health care contact. The remaining variables of the
ABCD2 and ABCD3 scores were collected in the ori-
ginal study.
Calculation of ABCD2 and ABCD3 scores
We calculated all variables for the ABCD2 and ABCD3
scores as defined elsewhere: [5] (A) Age <60 years 0
points and ≥60 years 1 point; (B) first recorded blood
pressure <140/90 0 points and either ≥140 systolic
or ≥90 diastolic 1 point; (C) clinical features of the pre-
senting event with focal weakness 2 points, speech im-
pairment without weakness 1 point, and other 0 points;
(D1) duration of presenting event <10 minutes 0 points,
10-59 minutes 1 point, and ≥60 minutes 2 points; (D2)
diabetes absent 0 points and present 1 point; and (D3)
for ABCD3-scores only, dual events with ≥1 additional
TIA or amaurosis fugax within 7 days of the presenting
event 2 points and no such event 0 points. All patients
with stroke or retinal artery occlusion as the presenting
event were assigned 2 points for duration.
Endpoint & analyses
We used the same endpoint as in the original ANSYS-
CAP study: Recurrent ipsilateral ischemic stroke. Ipsilat-
eral retinal artery occlusion was also included in the
endpoint (and is henceforth included in “ipsilateral is-
chemic stroke”). We analyzed recurrent ipsilateral stroke
within 14 days after the presenting event. If the patient
Table 1 Baseline patient data
All (n = 230)
Men n (%) 147 (64%)
Age, years mean (SD) 71 (7.7)
50-69% symptomatic carotid stenosis n (%) 54 (23%)
70-99% symptomatic carotid stenosis n (%) 176 (77%)
First recorded systolic blood pressure mean (SD) 160 (29)
First recorded diastolic blood pressure mean (SD) 82 (16)
Presenting event: Stroke n (%) 96 (42%)
Presenting event: Retinal artery occlusion n (%) 12 (5%)
Presenting event: TIA n (%) 70 (30%)
Presenting event: Amaurosis fugax n (%) 52 (23%)
Anti-platelet or anti-coagulant at first health
care contact n (%)
130 (57%)
Anti-platelet or anti-coagulant at 2 days after
first health care contact n (%)
195 (85%)
Anti-platelet or anti-coagulant at 7 days after
first health care contact n (%)
214 (93%)
Blood-pressure lowering medication at first
health care contact n (%)
189 (82%)
Blood-pressure lowering medication at 2
days after first health care contact n (%)
198 (86%)
Blood-pressure lowering medication at 7 days
after first health care contact n (%)
205 (89%)
Lipid lowering medication at first health care
contact n (%)
99 (43%)
Lipid lowering medication at 2 days after first
health care contact n (%)
142 (62%)
Lipid lowering medication at 7 days after first
health care contact n (%)
176 (77%)
Underwent CEA or carotid angioplasty n (%) 183 (80%)
Delay between presenting event and first health
care contact, days median (IQR)
0 (0-2)
Delay between presenting event and CEA or
carotid angioplasty, weeks median (IQR)
4.1 (2.4-7.1)
CEA or carotid angioplasty within 2 days of the
presenting event
1 (0.4%)
CEA or carotid angioplasty within 7 days of the
presenting event
10 (4%)
CEA or carotid angioplasty within 14 days of the
presenting event
36 (16%)
Recurrent ipsilateral ischemic stroke n (%) 25 (11%)
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that occurred before the CEA (excluding all periopera-
tive events). The presenting event was defined as the last
ischemic cerebrovascular event (stroke, retinal artery oc-
clusion, TIA, or amaurosis fugax) before the patient
sought health care.
We analyzed the risk of the endpoint at 2 days, 7 days,
and 14 days. We analyzed the risk of the endpoint for
each parameter in the ABCD2 and ABCD3 scores separ-
ately and for different total ABCD2 and ABCD3 scores.We analyzed an ABCD2 score of 2, 3, and 4 points as
cut-offs for high and low risk. We used the same cut-
offs for the ABCD3 score as in a previous study [8]: low
(0-3 points), moderate (4-5 points), and high (6-9 points)
risk.
Ethics
The local Ethical Review Board found the study to be
completely observational and therefore did not incur any
ethical problems and did not require ethics approval.
Statistics
We calculated the 14-day risk of recurrent ipsilateral is-
chemic stroke with Kaplan-Meier curves. We used CEA
as a censor and, therefore, patients that underwent CEA
only contributed risk-time before their CEA and all peri-
operative events were excluded. The risks at 2, 7, and
14 days were acquired from this survival analysis. We
used the log rank test for differences between groups. A
p-value <0.05 was defined as statistically significant. We
used IBM SPSS 20.0 Statistical software for all calculations.
Results
Data for age, first recorded blood pressure, clinical pres-
entation, diabetes, and dual events were available for all
230 cases. Five cases were excluded from analyses of the
event duration and total ABCD2 and ABCD3 scores be-
cause the duration of the presenting event could only be
determined as less than 24 hours. The mean observation
time was 12.3 (SD 3.6) days, 179 (78%) were observed
for 14 days.
When analyzing the parameters in the ABCD2 and
ABCD3 scores separately, only clinical presentation
(focal weakness, speech disturbance, or other focal neu-
rological deficit) tended to be a statistically significant
risk factor for recurrent ipsilateral ischemic stroke (p =
0.06, log rank test), see Table 2. Not one of the six
parameters was present in all 12 patients that suffered a
recurrent ischemic stroke within 2 days. A ≤3% risk of
recurrent ipsilateral ischemic stroke at 2 days was ob-
served among the patients without clinical presentation
of focal weakness or speech disturbance and the patients
with a presenting event lasting <10 minutes.
The risks of recurrent ipsilateral ischemic stroke for
different ABCD2 and ABCD3 scores are presented in
Table 3. Ninety-four percent of the patients had an
ABCD2 score ≥2 points, 84% had ≥3 points, and 76%
had ≥4 points. Seventeen percent of the patients had an
ABCD3 score of 0-3 points, 64% had 4-6 points, and
19% had 7-9 points. Of the 25 patients that suffered a
recurrent ipsilateral ischemic stroke within 14 days,
100% had an ABCD2 score ≥2 points, 96% had ≥3
points, and 92% had ≥4 points; while for ABCD3 scores,
0% had 0-3 points, 84% had 4-6 points, and 16% had 7-9
Table 2 Risk of recurrent ipsilateral ischemic stroke at 2, 7, and 14 days after the presenting event for each of the
parameters in the ABCD3 score
Pat 2 days 7 days 14 days P-value
n Risk n Risk n Risk
Age <60 years 19 1 5% (0-15%) 1 5% (0-15%) 2 11% (0-25%) p = 0.95
Age ≥60 years 211 11 5% (2-8%) 17 8% (4-12%) 23 11% (7-16%)
Blood Pressure <140/90 46 5 11% (2-20%) 7 15% (5-26%) 8 17% (6-28%) p = 0.10
Blood Pressure ≥140/90 184 7 4% (1-7%) 11 6% (2-10%) 17 10% (5-14%)
Clinical presentation: Other 64 2 3% (0-7%) 2 3% (0-7%) 2 3% (0-7%) p = 0.06
Clinical presentation: Speech disturbance 17 1 6% (0-17%) 3 18% (0-37%) 3 18% (0-37%)
Clinical presentation: Focal weakness 149 9 6% (2-10%) 13 9% (4-13%) 20 14% (8-20%)
Duration <10 min* 59 2 3% (0-8%) 2 3% (0-8%) 4 7% (0-14%) p = 0.45
Duration 10-59 min* 36 2 6% (0-13%) 5 14% (3-25%) 5 14% (3-25%)
Duration ≥60 min* 130 8 6% (2-10%) 11 9% (4-13%) 16 13% (7-18%)
Diabetes: Absent 168 9 5% (2-9%) 13 8% (4-12%) 18 11% (6-16%) p = 0.91
Diabetes: Present 62 3 5% (0-10%) 5 8% (1-15%) 7 12% (3-20%)
Dual events: Absent 183 10 5% (2-9%) 14 8% (4-12%) 19 11% (6-15%) p = 0.61
Dual events: Present 47 2 4% (0-10%) 4 9% (0-17%) 6 14% (3-25%)
*5 cases excluded because of unknown duration of the presenting event.
Risk data derived from Kaplan-Meier analyses using CEA as a censor.
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for the cut-off ABCD2 and ABCD3 scores are depicted
in Figure 1. We analyzed if the risk of ipsilateral ische-
mic stroke differed between various cut-offs for ABCD2
and ABCD3 scores. We found that the risk of recurrentTable 3 Risk of recurrent ipsilateral ischemic stroke at 2, 7, an
and ABCD3 scores
ABCD2 Pat (%)* 2 days
n Risk (95% CI)
0-1p 13 (6%) 0 -
2p 24 (11%) 1 4% (0-12%)
3p 16 (7%) 1 6% (0-18%)
4p 38 (17%) 4 11% (1-20%)
5p 36 (16%) 0 -
6p 71 (32%) 5 7% (1-13%)
7p 27 (12%) 1 4% (0-11%)
ABCD3 Pat (%)* 2 days
n Risk (95% CI)
0-3p 39 (17%) 0 -
4p 35 (16%) 5 14% (3-26%)
5p 37 (16%) 1 3% (0-8%)
6p 73 (32%) 5 7% (1-13%)
7p 30 (13%) 1 3% (0-10%)
8p 8 (4%) 0 -
9p 3 (1%) 0 -
*5 cases excluded because of unknown duration of the presenting event.
Risk data derived from Kaplan-Meier analyses using CEA as a censor.ipsilateral ischemic stroke tended to be statistically sig-
nificant for the ABCD2 cut-offs of ≥3 points (p = 0.08)
and ≥4 points (p = 0.06) and the ABCD3 categories 0-3,
4-5, and 6-9 points (p = 0.052), but not for the ABCD2
cut-off of ≥2 points (p = 0.19, log rank test).d 14 days after the presenting event based on ABCD2
7 days 14 days
n Risk (95% CI) n Risk (95% CI)
0 - 0 -
1 4% (0-12%) 1 4% (0-12%)
1 6% (0-18%) 1 6% (0-18%)
5 13% (2-24%) 7 19% (6-32%)
3 9% (0-18%) 4 11% (1-22%)
7 10% (3-17%) 10 14% (6-22%)
1 4% (0-11%) 2 8% (0-19%)
7 days 14 days
n Risk (95% CI) n Risk (95% CI)
0 - 0 -
6 17% (5-30%) 6 17% (5-30%)
3 8% (0-17%) 4 11% (1-21%)
6 8% (2-15%) 11 16% (7-24%)
2 7% (0-16%) 3 11% (0-22%)
1 13% (0-35%) 1 13% (0-35%)
0 - 0 -
Figure 1 Risks of recurrent ipsilateral ischemic stroke for different cut-off ABCD2 and ABCD3 scores. Risk data derived from Kaplan-Meier
analyses using CEA as a censor. Error bars denotes 95% CI.
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Among the patients with symptomatic 50-99% carotid
stenosis included in this study, 25 suffered a recurrent
ipsilateral ischemic stroke within 14 days and all of these
patients had an ABCD3 score ≥4 points. The overall ap-
proach is the main novelty of this article – although
ABCD-type score cannot detect a sufficient share of the
patients with carotid stenosis, they seem to be able to
detect a sufficient share of the patients with carotid sten-
osis that suffer an early recurrent ipsilateral ischemic
stroke. However, due a small sample size, no firm con-
clusions can be drawn.
None of the other parameters could predict all the re-
current ipsilateral strokes that occurred within 2 days.
However, both an ABCD2 score ≥2 points and an
ABCD3 score ≥4 points were able to predict all events at
2 days as well as at 14 days. There were more patients
without recurrent strokes with ABCD3 scores <4 points
(17%) than ABCD2 scores <2 points (6%); therefore, it is
reasonable to regard the ABCD3 score as clinically more
useful for triaging to acute or delayed carotid imaging.
Similarly, in TIA patients with mixed etiologies, 8.0%
(208/2611) have an ABCD2 score <2 points and 33%
(802/2445) have an ABCD3 score <4 points (Personal
communication with PJ Kelly and Á Merwick in 2013
regarding [5]). In addition, the ABCD2 cut-off of <2
points was non-significant, but this is likely a false nega-
tive finding caused by a low number (n = 13) of patients
with <2 points.
Our data confirm the findings of previous studies that
an ABCD2 score <4 points does not detect all patients
with carotid stenosis [8,14-17]. Since a symptomatic ca-
rotid stenosis incurs a high risk of stroke recurrence, we
concur with Merwick and colleagues [5] that carotid im-
aging should generally be performed within 24 hours inall TIA/minor ischemic stroke patients eligible for CEA.
It may not be meaningful to triage patients to delayed
carotid imaging in clinical settings with general 24/7 ac-
cess to acute carotid imaging; although, a cost-benefit
analysis is warranted. However, it is our experience that
there are clinical settings (small rural hospitals) with
limited access to carotid imaging (whether the patient is
admitted or not) and too long distances for regular
transfers. In such settings there is a need for an evidence
based way to triage patients to carotid imaging. In such
settings, it is likely that this will incur benefit rather than
harm because the patient with the highest risk is examined
first. Our results points to that an ABCD3 score of <4 can
be used for this triage. Since an ABCD3 score <4 is quite
rare (17%) among patients with carotid stenosis, one
could question if such a triage system would be meaning-
ful. However, such a triage system would be meaningful
because in the intended population (patients with TIA of
mixed etiologies), an ABCD3 score of <4 is more com-
mon – 33% (Personal communication with PJ Kelly and
Á Merwick in 2013 regarding [5]).
The risk reducing effect of CEA seems to occur within
the first 3 years [20]. Therefore, although our 2, 7, and
14 day risks might be used for triage before CEA, it
would be inappropriate to base the decision to perform
CEA on our results.
Several aspects of the current study design should be
considered. The issue of timing in carotid imaging is
mainly of interest for patients that might be eligible for
CEA and we only included patients who were preli-
minarily eligible for CEA. In addition, our outcome was
ipsilateral ischemic stroke, which is the serious outcome
most likely to be preventable by early CEA. Since the
issue of the timing of carotid imaging is focused on
the risk before CEA, we censored patients after they
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A few patients with a major recurrent stroke that oc-
curred before they were referred to the Umeå Stroke
Center were likely missed. The results are not valid for
all patients with symptomatic carotid stenosis because
we excluded those not preliminarily eligible for CEA
because of major stroke as the presenting event, ad-
vanced age, or serious co-morbidities. Although much
larger than the previous similar study [18], the sample
size (n = 230 with 25 strokes) was small and, therefore,
we were not able to analyze patients with presenting
events lasting <24 hours alone. This is a small hypoth-
esis generating study and the findings in this study need
to be validated. This is likely achievable by re-analyzing
the cohorts with carotid stenosis as a risk factor rather
than analyzing patients with carotid stenosis separately
[4,5,21,22].
Conclusion
Although some patients with symptomatic 50-99% ca-
rotid stenosis had low ABCD2 and ABCD3 scores, none
of these patients suffered a recurrent ipsilateral ischemic
stroke before CEA. Although our findings need to be
validated and confirmed in further studies, our results
suggest an ABCD3 score of 0-3 or ≥4 might be used for
triaging patients to delayed or acute carotid imaging in
clinical settings with limited access to carotid imaging.
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